CD8A and neoplasm: Preclinical studies reveal that HPV antigen-specific TILs combined with anti-PD-1 therapy significantly enhance CD8+ T cell infiltration while reducing immunosuppressive cells (e.g., Tregs, MDSCs), achieving higher tumor regression rates than breast or lung cancer models (111, 113).